JCM
RPRX icon

Jacobi Capital Management’s Royalty Pharma RPRX Stock Holding History

Jacobi Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-102
Closed -$4K – 1124
2021
Q3 		$4K Hold
102
– – ﹤0.01% 1237
2021
Q2 		$4K Buy
+102
New +$4.34K ﹤0.01% 1200

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jacobi Capital Management's RPRX Position: Q4 2021 in Review

Jacobi Capital Management sold out of Royalty Pharma (RPRX) in Q4 2021, closing a stake of 102 shares — an estimated $4K sold.

Jacobi Capital Management first reported a position in RPRX in Q2 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 266 funds tracked by Wall St. Rank hold RPRX as of Q4 2021.

  • Jacobi Capital Management reported no remaining Royalty Pharma position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 102 Royalty Pharma shares in Q4 2021, an estimated $4K.
  • Jacobi Capital Management first reported a position in Royalty Pharma in Q2 2021 and held it in 2 quarters.
  • Jacobi Capital Management's Royalty Pharma position peaked at $4K in Q3 2021.
  • 266 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.